Merck Canada And The Pan-Canadian Pharmaceutical Alliance Have Completed Negotiations For WELIREG, Indicating The Next Step Will Involve Provincial And Territorial Governments, And Federal Drug Programs Implementing Reimbursement For Their Respective Jurisdictions

Approved indications include the treatment of adult patients with von Hippel-Lindau (VHL) disease for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or non-metastatic pancreatic neuroendocrine tumours (pNET), not requiring immediate surgery

KIRKLAND, QC, Sept. 5, 2024 /CNW/ - Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for WELIREG (belzutifan) on August 30th. The pCPA negotiates on behalf of the provinces, territories, and federal drug programs, serving as a critical step in bringing WELIREG closer to public reimbursement.

Reaching this significant milestone is the outcome of close collaboration with the pCPA and highlights the necessity to progress quickly towards public reimbursement. The next step will involve provincial and territorial governments, and federal drug programs implementing reimbursement for their respective jurisdictions.